Abstract : Graves' disease is the most common autoimmune disease, affecting 0.5% of the population in the US, and represents 50–80% of cases of hyperthyroidism. Unanimous consensus exists about the significant morbidities associated with Graves’ disease. Thus, prevention of metabolic syndrome hopefully, will then be able to reduce the already significant disease burden in the country. To find out the incidence of the metabolic syndrome in patients who after receiving pharmacotherapy with thionamides have achieved clinical and biochemical euthyroid status and to evaluate the clinical and biochemical parameters pertaining to the incidence of the metabolic syndrome in patients with Graves’ disease under control. A observational study were conducted among 96 graves’ disease patient with clinical and biochemical euthyroid status after pharmacotherapy who visited a tertiary care hospital in Kolkata. Through systemic random sampling technique, the required number of samples were collected and tested for clinical signs and biochemical parameters pertaining to metabolic syndrome as given in the IDF (2006) criteria. Statistical analysis was done using SPSSv22. 36.05% of the study population developed metabolic syndrome as per the IDF criteria after achieving clinical and biochemical euthyroid status with pharmacotherapy. 29 of the 31 patients who developed metabolic syndrome had BMI within normal range at the diagnosis of Graves’ disease. Proper diet habits, lifestyle modification, appropriate pharmacotherapy and regular follow-up together will predict and prevent the risk of metabolic syndrome as a whole. Reducing risk of metabolic syndrome helps patients to achieve sound health to carry out activities to gain financial stability.